Skip to main navigation Skip to search Skip to main content

The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

  • Sizheng Zhao*
  • , Stephanie R Harrison
  • , Ben Thompson
  • , Max Yates
  • , Joe Eddison
  • , Antoni Chan
  • , Nick Clarke
  • , Nadia Corp
  • , Charlotte Davis
  • , Lambert Felix
  • , Kalveer Flora
  • , William J Gregory
  • , Gareth T Jones
  • , Christopher A Lamb
  • , Helena Marzo-Ortega
  • , Daniel J. Murphy
  • , Harry Petrushkin
  • , Virinderjit Sandhu
  • , Raj Sengupta
  • , Stefan Siebert
  • Danielle A van der Windt, Dale Webb, Zenas Yiu, Karl Gaffney
*Corresponding author for this work
  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust
  • Norfolk & Norwich University Hospital NHS Foundation Trust
  • Royal Berkshire NHS Foundation Trust
  • University of Keele
  • Leeds Teaching Hospitals NHS Trust
  • London North West Healthcare NHS Trust
  • Royal Devon & Exeter Nhs Foundation Trust (Applica
  • Moorfields Eye Hospital NHS Foundation Trust
  • St George's University Hospitals NHS Foundation Trust
  • Royal United Hospital Bath NHS Trust
  • University of Glasgow
  • National Axial Spondyloarthritis Society

Research output: Contribution to journal › Article › peer-review

13 Downloads (Pure)
Original languageEnglish
Article numberkeaf089
JournalRheumatology
Early online date9 Apr 2025
DOIs
Publication statusPublished - 9 Apr 2025

Keywords

  • axSpA
  • ankylosing spondylitis
  • biologics
  • targeted synthetic DMARDs
  • treatment
  • management
  • guidline
  • recommendations
  • extra-musculoskeletal maninfestations
  • uveitis
  • psoriasis
  • inflammatory bowel disease

Cite this